Companies

Enovis CORP

ENOV · CIK 0001420800 · operating

$25.70+0.90%Last updated Mar 3, 12:02 AM

Key Statistics

Valuation

Market Cap$1.47B
P/E
Fwd P/E6.52
PEG
P/S0.65
P/B0.99
EV/EBITDA7.66
EV/Rev1.25

Profitability

Gross Margin59.84%
Op. Margin-50.01%
Net Margin-52.69%
ROE-79.51%
ROA-30.89%
FCF Margin0.89%

Financial Health

Current Ratio2.02
Debt/Equity1.57
Free Cash Flow$19.92M
Div. Yield

Growth & Other

Revenue Growth6.66%
EPS Growth-38.98%
Beta1.62
52W High$40.7
52W Low$21

About Enovis CORP

Enovis Corporation is a medical technology company that develops and manufactures orthopedic and reconstructive solutions for surgical and non-surgical applications. The company operates primarily in the United States and internationally, serving orthopedic specialists, surgeons, primary care physicians, physical therapists, athletic trainers, and other healthcare professionals. Its product portfolio spans orthopedic bracing, thermal therapy systems, bone growth stimulators, vascular therapy devices, compression garments, electrical stimulators, and physical therapy equipment used across pain management, rehabilitation, and recovery applications.

The company operates through two business segments. The Prevention and Recovery segment provides non-invasive orthopedic solutions including rigid and soft bracing, therapeutic footwear and inserts, and recovery-focused devices. The Reconstructive segment manufactures surgical implants for joint reconstruction procedures in the hip, knee, shoulder, elbow, foot, ankle, and finger, alongside surgical productivity tools designed to enhance operative efficiency.

Enovis distributes its products through a combination of independent distributors and direct channels under the ESAB and DJO brand names. The company was incorporated in Delaware and is headquartered in Wilmington. Originally founded in 1995, Enovis was formerly known as Colfax Corporation before undergoing its current organizational structure.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2025$-20.75$-20.75-39.0%
2024$-14.93$-14.93-2347.5%
2023$-0.61$-0.61+14.1%
2022$-0.71$-0.71-254.3%
2021$0.46$0.47+91.7%
2020$0.24$0.24+300.0%
2019$-0.12$-0.12-209.1%
2017$0.11$0.11-89.4%
2016$1.04$1.04+188.9%
2015$0.36$0.36-43.8%
2014$0.64$0.65+106.5%
2013$0.31$0.31+138.5%
2012$0.13$0.14
2011

Annual Reports (10-K) · 11 filings

Report DateFiledAccession Number
2025-12-312026-02-260001420800-26-000012SEC ↗
2024-12-312025-02-260001420800-25-000009SEC ↗
2023-12-312024-02-220001420800-24-000006SEC ↗
2022-12-312023-03-010001420800-23-000008SEC ↗
2021-12-312022-02-220001420800-22-000004SEC ↗
2020-12-312021-02-180001420800-21-000009SEC ↗
2019-12-312020-02-240001420800-20-000005SEC ↗
2018-12-312019-02-210001420800-19-000002SEC ↗
2017-12-312018-02-160001420800-18-000004SEC ↗
2016-12-312017-02-140001420800-17-000004SEC ↗
2015-12-312016-02-160001420800-16-000047SEC ↗